GRP logo
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report-Part III

The citation for this report is:
Mansley EC, Carroll NV, Chen KS, et al. Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report-Part III. Value Health 2010;13:14-17.

Task Force Leadership Group
Edward C. Mansley PhD, Managed Care Subgroup Chair & Associate Director, Health Economics, U.S. Outcomes Research, Merck & Co., Inc., North Wales, PA, USA
Norman V. Carroll RPh, PhD, Professor of Pharmacy Administration, Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA
Kristina S. Chen PharmD, MS, Associate, Analysis Group, Boston, MA, USA
Nilay D. Shah PhD, RPh, Assistant Professor of Health Services Research, Mayo Clinic, Rochester, MN, USA
Catherine Tak Piech MBA, Vice President, Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

For recommendations on how drug costs should be measured for cost-effectiveness analysis from other key analytic perspectives, please refer to the following reports:

FINAL REPORT
The Drug Cost Standards Task Force presented their reports including responses to member comments during an open forum at ISPOR’s 14th Annual International Meeting in Orlando, FL in May 2009.  The task force’s forum presentation can be viewed at: Forum Presentation


ISPOR Good Practices For Outcomes Research Index